2026 Q2 - tulosraportti
86 päivää sitten
‧48 min
1,00 NOK/osake
Viimeisin osinko
36,56%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 524 | ||
| 524 | ||
| 340 | ||
| 203 | ||
| 912 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 23.11. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenvirtually no change in holdings on the top50 list the last month, while turnover has been approx 20mill and the share price down close to 20%. Algos just working down the price? Betting on a rebound Monday.Incomprehensible that the shareholders step up with a private placement at 4,4, only for the share price to drop to 2,7. Rasmussen even has a board seat, and has been involved in deciding the terms. Clearly they know more...
- ·9 t sittenExcerpt from yesterday's stock exchange announcement. Those who throw themselves in now will miss out on all the fun: Management in Nykode will participate in three sessions during the summit, where they will share the company's perspectives on the development, production, and clinical implementation of personalized cancer vaccines. "As interest in the field of individualized neoantigen cancer vaccines grows, attention is increasingly turning to how these treatments can be made available to patients on a large scale," says Agnete Fredriksen, Chief Scientific Officer and co-founder of Nykode Therapeutics. "We believe that our DNA platform, which targets antigen-presenting cells (APCs), offers a unique approach. This is supported by promising clinical data for immune response and an established manufacturing process. We look forward to contributing to discussions on the opportunities and challenges that will shape the future of personalized cancer vaccines." Nykode's work with personalized cancer vaccines is continued through VB10.NEO – a wholly-owned, DNA-based therapy based on individualized neoantigens (INT). VB10.NEO builds on Nykode's proprietary technology for targeting antigen-presenting cells (APCs), as well as NeoSELECT™, an AI-driven engine for the selection of neoantigens. The solution is designed to deliver selected antigens to APCs, with the goal of generating broad, potent, and long-lasting antigen-specific immune responses. The company has established a comprehensive manufacturing process for VB10.NEO, and has achieved a 100% success rate in production across two clinical studies. Further optimization of the manufacturing process has reduced the time from biopsy to finished product to under six weeks, with good opportunities for further time savings through the consolidation of operations under "one roof". The plasmid DNA-based platform also offers potential advantages regarding manufacturing complexity and costs, compared to other approaches. Clinical data from two studies in patients with advanced solid tumors show vaccine-specific immune responses in 88–100% of patients, including newly formed (de novo) T-cell responses in 85% of patients. These responses persisted for more than one year after the last dose, which underpins the potential of Nykode's platform to generate strong and sustained immune responses.
- ·9 t sittenIt is just to average down while we are at full speed towards all-time low! New report on Monday that will surely send us further downwards. Lovely to feel that you are alive!
- ·1 päivä sittenhttps://lnkd.in/p/ebWN77qZ Positive phase 3 results from SELLAS strengthen the credibility of cancer vaccines as a treatment form, especially now that improved overall survival has been documented.
- 1 päivä sittenShowcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit https://newsweb.oslobors.no/message/687007
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
86 päivää sitten
‧48 min
1,00 NOK/osake
Viimeisin osinko
36,56%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenvirtually no change in holdings on the top50 list the last month, while turnover has been approx 20mill and the share price down close to 20%. Algos just working down the price? Betting on a rebound Monday.Incomprehensible that the shareholders step up with a private placement at 4,4, only for the share price to drop to 2,7. Rasmussen even has a board seat, and has been involved in deciding the terms. Clearly they know more...
- ·9 t sittenExcerpt from yesterday's stock exchange announcement. Those who throw themselves in now will miss out on all the fun: Management in Nykode will participate in three sessions during the summit, where they will share the company's perspectives on the development, production, and clinical implementation of personalized cancer vaccines. "As interest in the field of individualized neoantigen cancer vaccines grows, attention is increasingly turning to how these treatments can be made available to patients on a large scale," says Agnete Fredriksen, Chief Scientific Officer and co-founder of Nykode Therapeutics. "We believe that our DNA platform, which targets antigen-presenting cells (APCs), offers a unique approach. This is supported by promising clinical data for immune response and an established manufacturing process. We look forward to contributing to discussions on the opportunities and challenges that will shape the future of personalized cancer vaccines." Nykode's work with personalized cancer vaccines is continued through VB10.NEO – a wholly-owned, DNA-based therapy based on individualized neoantigens (INT). VB10.NEO builds on Nykode's proprietary technology for targeting antigen-presenting cells (APCs), as well as NeoSELECT™, an AI-driven engine for the selection of neoantigens. The solution is designed to deliver selected antigens to APCs, with the goal of generating broad, potent, and long-lasting antigen-specific immune responses. The company has established a comprehensive manufacturing process for VB10.NEO, and has achieved a 100% success rate in production across two clinical studies. Further optimization of the manufacturing process has reduced the time from biopsy to finished product to under six weeks, with good opportunities for further time savings through the consolidation of operations under "one roof". The plasmid DNA-based platform also offers potential advantages regarding manufacturing complexity and costs, compared to other approaches. Clinical data from two studies in patients with advanced solid tumors show vaccine-specific immune responses in 88–100% of patients, including newly formed (de novo) T-cell responses in 85% of patients. These responses persisted for more than one year after the last dose, which underpins the potential of Nykode's platform to generate strong and sustained immune responses.
- ·9 t sittenIt is just to average down while we are at full speed towards all-time low! New report on Monday that will surely send us further downwards. Lovely to feel that you are alive!
- ·1 päivä sittenhttps://lnkd.in/p/ebWN77qZ Positive phase 3 results from SELLAS strengthen the credibility of cancer vaccines as a treatment form, especially now that improved overall survival has been documented.
- 1 päivä sittenShowcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit https://newsweb.oslobors.no/message/687007
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 524 | ||
| 524 | ||
| 340 | ||
| 203 | ||
| 912 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 23.11. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
86 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 23.11. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
1,00 NOK/osake
Viimeisin osinko
36,56%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenvirtually no change in holdings on the top50 list the last month, while turnover has been approx 20mill and the share price down close to 20%. Algos just working down the price? Betting on a rebound Monday.Incomprehensible that the shareholders step up with a private placement at 4,4, only for the share price to drop to 2,7. Rasmussen even has a board seat, and has been involved in deciding the terms. Clearly they know more...
- ·9 t sittenExcerpt from yesterday's stock exchange announcement. Those who throw themselves in now will miss out on all the fun: Management in Nykode will participate in three sessions during the summit, where they will share the company's perspectives on the development, production, and clinical implementation of personalized cancer vaccines. "As interest in the field of individualized neoantigen cancer vaccines grows, attention is increasingly turning to how these treatments can be made available to patients on a large scale," says Agnete Fredriksen, Chief Scientific Officer and co-founder of Nykode Therapeutics. "We believe that our DNA platform, which targets antigen-presenting cells (APCs), offers a unique approach. This is supported by promising clinical data for immune response and an established manufacturing process. We look forward to contributing to discussions on the opportunities and challenges that will shape the future of personalized cancer vaccines." Nykode's work with personalized cancer vaccines is continued through VB10.NEO – a wholly-owned, DNA-based therapy based on individualized neoantigens (INT). VB10.NEO builds on Nykode's proprietary technology for targeting antigen-presenting cells (APCs), as well as NeoSELECT™, an AI-driven engine for the selection of neoantigens. The solution is designed to deliver selected antigens to APCs, with the goal of generating broad, potent, and long-lasting antigen-specific immune responses. The company has established a comprehensive manufacturing process for VB10.NEO, and has achieved a 100% success rate in production across two clinical studies. Further optimization of the manufacturing process has reduced the time from biopsy to finished product to under six weeks, with good opportunities for further time savings through the consolidation of operations under "one roof". The plasmid DNA-based platform also offers potential advantages regarding manufacturing complexity and costs, compared to other approaches. Clinical data from two studies in patients with advanced solid tumors show vaccine-specific immune responses in 88–100% of patients, including newly formed (de novo) T-cell responses in 85% of patients. These responses persisted for more than one year after the last dose, which underpins the potential of Nykode's platform to generate strong and sustained immune responses.
- ·9 t sittenIt is just to average down while we are at full speed towards all-time low! New report on Monday that will surely send us further downwards. Lovely to feel that you are alive!
- ·1 päivä sittenhttps://lnkd.in/p/ebWN77qZ Positive phase 3 results from SELLAS strengthen the credibility of cancer vaccines as a treatment form, especially now that improved overall survival has been documented.
- 1 päivä sittenShowcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit https://newsweb.oslobors.no/message/687007
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 524 | ||
| 524 | ||
| 340 | ||
| 203 | ||
| 912 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt






